All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV.7m8-Aflibercept
Therapeutic Area: Ophthalmology Product Name: ADVM-022
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
ADVM-022 is a single in-office intravitreal injection therapy that has shown promising efficacy and safety for over two years in patients with wet AMD in the OPTIC trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sunitinib
Therapeutic Area: Ophthalmology Product Name: GB-102
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
Graybug’s lead product candidate, GB-102, is a proprietary microparticle depot formulation of the pan-vascular endothelial growth factor (pan-VEGF) inhibitor, sunitinib malate, designed to be administered intravitreally twice per year.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Corticosteroid
Therapeutic Area: Ophthalmology Product Name: SURF-201
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
SURF-201 (betamethasone 0.2% in Klarity®) is being studied for the treatment of pain and inflammation following ocular surgery. Results from the Phase II trial for SURF-201 are expected in the early part of 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HMR59
Therapeutic Area: Ophthalmology Product Name: HMR59
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Janssen Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 02, 2020
Details:
Acquisition of gene therapy HMR59, significantly expands Janssen's eye disease portfolio and strengthens its gene therapy capabilities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Recombinant human complement Factor H
Therapeutic Area: Ophthalmology Product Name: GEM103
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Results showed that, in the four ascending single IVT doses tested (50, 100, 250 and 500 µg of GEM103 in a 50µL dose volume), there were no inflammation, anti-drug antibody, or treatment-related adverse events. A single intravitreal injection of GEM103 met safety endpoint.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ngm621
Therapeutic Area: Ophthalmology Product Name: NGM621
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular inflammation or choroidal neovascularization.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RGX-314
Therapeutic Area: Ophthalmology Product Name: RGX-314
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
Company will deliver two oral presentations will be presented at the American Academy Ophthalmology (AAO) 2020 Annual Meeting. The first presentation will feature data from the RGX-314 Phase I/II subretinal trial for the treatment of wet age-related macular degeneration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Elamipretide
Therapeutic Area: Ophthalmology Product Name: MTP-131
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Morningside Ventures
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 04, 2020
Details:
The agreement will enable company's clinical development of elamipretide, Phase 2b study in geographic atrophy and prepare to file our first NDA for elamipretide for the treatment of Barth syndrome.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AR-15512
Therapeutic Area: Ophthalmology Product Name: AVX012
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
The COMET-1 trial is a randomized, double-masked, vehicle-controlled trial evaluating the efficacy and safety of AR-15512 (TRPM8 agonist) in patients with dry eye disease. AR-15512 is a TRPM8 agonist for the treatment of patients with dry eye disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ciclosporin
Therapeutic Area: Ophthalmology Product Name: OTX-CSI
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
